SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?


To: Dr. John M. de Castro who wrote (383)11/13/1998 5:31:00 PM
From: JMarcus  Read Replies (1) | Respond to of 1494
 
I checked my notes and still don't recall any hints about who the 4 suitors might be, but my impression is that they are of the big pharma variety.

A couple of my favorite quotes from the meeting.

Freiman: "Memantine looks like a real drug. That is rare. And the world doesn't know it yet."

Cohen: "This is the first time that I have a feeling that we really have a product. . . . It is not often that one finds oneself in this position." He went on to say that he still has a lot of connections from his former days with Merck. He promised the stockholders that he would be working the telephone this weekend, trying to raise money.

JMarcus



To: Dr. John M. de Castro who wrote (383)12/22/1998 11:29:00 AM
From: BRAVEHEART  Respond to of 1494
 
Hi John,

Do you or does anyone have any projections on the potential total sales ( in dollars ) for Memantine for both indications? How about for Xiracept?

Jeffrey